REFERENCES
1. Grünewald TG, Alonso M, Avnet S, et al. Sarcoma treatment in the era of molecular medicine. EMBO Mol Med 2020;12:e11131.
2. Hayes AJ, Nixon IF, Strauss DC, et al. UK guidelines for the management of soft tissue sarcomas. Br J Cancer 2024;Online ahead of print.
3. Tellez-Gabriel M, Brown HK, Young R, Heymann MF, Heymann D. The challenges of detecting circulating tumor cells in sarcoma. Front Oncol 2016;6:202.
4. Lin D, Shen L, Luo M, et al. Circulating tumor cells: biology and clinical significance. Signal Transduct Target Ther 2021;6:404.
5. Brown HK, Tellez-Gabriel M, Cartron PF, Vallette FM, Heymann MF, Heymann D. Characterization of circulating tumor cells as a reflection of the tumor heterogeneity: myth or reality? Drug Discov Today 2019;24:763-72.
6. Satelli A, Mitra A, Cutrera JJ, et al. Universal marker and detection tool for human sarcoma circulating tumor cells. Cancer Res 2014;74:1645-50.
7. Hvichia GE, Parveen Z, Wagner C, et al. A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells. Int J Cancer 2016;138:2894-904.
8. Le MN, Smith KA, Dopico PJ, et al. Investigating surface proteins and antibody combinations for detecting circulating tumor cells of various sarcomas. Sci Rep 2024;14:12374.
9. Mu H, Zuo D, Chen J, et al. Detection and surveillance of circulating tumor cells in osteosarcoma for predicting therapy response and prognosis. Cancer Biol Med 2022;19:1397-409.
10. Vincenzi B, Rossi E, Zoccoli A, et al. Circulating tumor cells in soft tissue sarcomas patients. Ann Oncol 2012;23:ix489.
11. Blanchi J, Laroche-Clary A, Le Loarer F, Bonhomme B, Italiano A. Prognostic impact of circulating tumor cells in patients with soft-tissue sarcomas: a prospective study. Cancer Commun 2023;43:391-4.
12. Vismara M, Reduzzi C, Silvestri M, et al. Single-cell phenotypic and molecular characterization of circulating tumor cells isolated from cryopreserved peripheral blood mononuclear cells of patients with lung cancer and sarcoma. Clin Chem 2022;68:691-701.
13. Hayashi M, Zhu P, McCarty G, et al. Size-based detection of sarcoma circulating tumor cells and cell clusters. Oncotarget 2017;8:78965-77.
14. Chinen LT, Mello CA, Abdallah EA, et al. Isolation, detection, and immunomorphological characterization of circulating tumor cells (CTCs) from patients with different types of sarcoma using isolation by size of tumor cells: a window on sarcoma-cell invasion. Onco Targets Ther 2014;7:1609-17.
15. Schleiermacher G, Peter M, Oberlin O, et al; Société Française d'Oncologie Pédiatrique. Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor. J Clin Oncol 2003;21:85-91.
16. Yang J, Du X, Wang G, et al. Mesenchymal to epithelial transition in sarcomas. Eur J Cancer 2014;50:593-601.
17. Callegaro D, Miceli R, Bonvalot S, et al. Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors. EClinicalMedicine 2019;17:100215.
18. Jones RL, Ravi V, Brohl AS, et al. Efficacy and safety of TRC105 plus pazopanib vs pazopanib alone for treatment of patients with advanced angiosarcoma: a randomized clinical trial. JAMA Oncol 2022;8:740-7.
